Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.51 |
| ▸ | TYR | P14679 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6796891 | 1.00 | GAA (0.60) | GAAALDH1A1CNR1CA1CA2 | |
| SCHEMBL6807898 | 1.00 | GAA (0.60) | GAAALDH1A1CNR1CA1CA2 | |
| SCHEMBL6802441 | 0.91 | GAA (0.72) | GAAALDH1A1CNR1CA1CA2 | |
| SCHEMBL6802437 | 0.91 | GAA (0.72) | GAAALDH1A1CNR1CA1CA2 | |
| SCHEMBL6803833 | 0.90 | ALDH1A1 (0.58) | ALDH1A1CA1CA2NOX4MTNR1A | |
| SCHEMBL6803831 | 0.90 | ALDH1A1 (0.58) | ALDH1A1CA1CA2NOX4MTNR1A | |
| SCHEMBL6798750 | 0.86 | GAA (0.53) | GAAALDH1A1CNR1CA1CA2 | |
| SCHEMBL6798746 | 0.86 | GAA (0.53) | GAAALDH1A1CNR1CA1CA2 | |
| SCHEMBL6798948 | 0.86 | GAA (0.53) | GAAALDH1A1CNR1CA1CA2 | |
| SCHEMBL27593581 | 0.85 | MTNR1A (0.61) | GAAALDH1A1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6762321-B2 | SUCH AS N-(2-(3,4-DIMETHOXYPHENYL)ETHYL)-3-DIFLUOROMETHOXY-2-(4 -METHYLPHENYL)ACRYLAMIDE; FUNGICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-07-13 | — | — | US | disclosed |
| US-20030195354-A1 | Amide compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-10-16 | — | — | US | disclosed |
| EP-1295868-A1 | AMIDE COMPOUNDS AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195354-A1 | Amide compounds and use thereof | CBR1, CBR3, NAT1 | GAA 2282/4885ALDH1A1 244/4885CNR1 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.